Last reviewed · How we verify

NCT05344625: KAPTIVATED

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

Withdrawn EARLY_PHASE1 Last updated 24 January 2024
What this trial tests

EARLY_PHASE1 trial testing Ketamine 100 MG/ML in Cancer-related Problem/Condition. Withdrawn.

Timeline
31 October 2023
Primary endpoint
15 March 2024
15 March 2024

Quick facts

Lead sponsorNorthwell Health
PhaseEARLY_PHASE1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date31 October 2023
Primary completion15 March 2024
Estimated completion15 March 2024

Drugs / interventions tested

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

Adults 21 to 65, any sex, with Cancer-related Problem/Condition or Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will investigate if ketamine-assisted psychotherapy during palliative radiation therapy is safe, feasible, and effective at reducing psychological distress.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer-related Problem/Condition

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05344625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing